Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

50.0%

1 terminated out of 2 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

2Total
P 1 (2)

Trial Status

Terminated1
Recruiting1

Clinical Trials (2)

Showing 2 of 2 trials
NCT04389632Phase 1Recruiting

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

NCT04665921Phase 1Terminated

A Study of SGN-STNV in Advanced Solid Tumors

Showing all 2 trials

Research Network

Activity Timeline